HEALEY ALS Platform Trial - Regimen I NUZ-001 The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS
Sean M. Healey AMG Center for ALS Announces First Participant . . . The trial will evaluate NUZ-001, an oral therapy that targets key pathological mechanisms in ALS, including TDP-43 protein aggregation and impaired autophagy, which are central features across multiple neurodegenerative diseases
Clinical Trials - Neurizon Therapeutics At Neurizon Therapeutics, we are committed to advancing innovative research in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) Our clinical development programs are designed to rigorously evaluate the safety and investigational profile of NUZ-001 through ethically conducted and regulator-approved clinical trials
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial NUZ-001 is in development for treating amyotrophic lateral sclerosis (ALS) It aims to address key pathological mechanisms, including TDP-43 protein aggregation and impaired autophagy, which are
Neurizon Therapeutics NUZ-001 (S-Monepantel) has completed Phase 1 and Open Label Extension (OLE) studies in a small cohort of people living with ALS, where treatment appeared safe and generally well tolerated, with encouraging signals observed across exploratory clinical measures
NUZ-001 | ALZFORUM In a February 2025 webinar, the company claimed that NUZ-001 had dose-dependently corrected the mislocalization of TDP-43, and reversed its aggregation, in ALS patient-derived induced pluripotent stems cells